- Home
- Publications
- Publication Search
- Publication Details
Title
Emerging oral drug options for ulcerative colitis
Authors
Keywords
-
Journal
EXPERT OPINION ON EMERGING DRUGS
Volume 28, Issue 3, Pages 191-201
Publisher
Informa UK Limited
Online
2023-09-05
DOI
10.1080/14728214.2023.2254686
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study
- (2023) William J. Sandborn et al. Clinical Gastroenterology and Hepatology
- Efficacy and safety of advanced oral small molecules for inflammatory bowel disease: Systematic review and meta-analysis
- (2023) Virginia Solitano et al. Journal of Crohns & Colitis
- Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies
- (2023) William J Sandborn et al. LANCET
- Reversibility of Frail Phenotype in Patients with Inflammatory Bowel Diseases
- (2023) Silvia Salvatori et al. Journal of Clinical Medicine
- Dual Biologic Therapy in Patients with Rheumatoid Arthritis and Psoriatic Arthritis
- (2023) Victoria Furer et al. Rambam Maimonides Medical Journal
- DOP42 Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with moderately-to-severely active Ulcerative Colitis: 12-week results from the Phase 2 LATTICE-UC study
- (2022) S Danese et al. Journal of Crohns & Colitis
- Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
- (2022) Steven R. Ytterberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effectiveness of ustekinumab in patients with refractory Crohn’s disease: a multicentre real-life study in Italy
- (2022) Maria Lia Scribano et al. Therapeutic Advances in Gastroenterology
- Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib
- (2022) Kevin L Winthrop et al. INFLAMMATORY BOWEL DISEASES
- Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials
- (2022) Silvio Danese et al. LANCET
- AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
- (2022) Katsuyoshi Matsuoka et al. Lancet Gastroenterology & Hepatology
- Efficacy and Safety of Ivarmacitinib in Patients with Moderate-to-Severe, Active, Ulcerative Colitis: A Phase II Study
- (2022) Baili Chen et al. GASTROENTEROLOGY
- ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension
- (2022) Severine Vermeire et al. Lancet Gastroenterology & Hepatology
- Frail Phenotype in Patients With Inflammatory Bowel Disease
- (2022) Silvia Salvatori et al. INFLAMMATORY BOWEL DISEASES
- ECCO Guidelines on Inflammatory Bowel Disease and Malignancies
- (2022) Hannah Gordon et al. Journal of Crohns & Colitis
- Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study
- (2021) Séverine Vermeire et al. Journal of Crohns & Colitis
- Respiratory Tract Infections in Inflammatory Bowel Disease Patients Taking Vedolizumab: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- (2021) Irene Marafini et al. Frontiers in Pharmacology
- Induction and long-term follow-up with ABX464 for moderate-to-severe ulcerative colitis: Results of phase 2a trial
- (2021) Severine Vermeire et al. GASTROENTEROLOGY
- STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
- (2021) Dan Turner et al. GASTROENTEROLOGY
- PTG-100, an Oral α4β7 Antagonist Peptide: Preclinical Development and Phase 1 and 2a Studies in Ulcerative Colitis
- (2021) William Sandborn et al. GASTROENTEROLOGY
- Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial
- (2021) Brian G Feagan et al. LANCET
- Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open‐label, long‐term extension study with up to 7.0 years of treatment
- (2021) William J. Sandborn et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment
- (2021) Tim Raine et al. Journal of Crohns & Colitis
- Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis
- (2021) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- The influence of cytokines on the complex pathology of ulcerative colitis
- (2021) Hiroshi Nakase et al. AUTOIMMUNITY REVIEWS
- Pre-treatment Frailty Is Independently Associated With Increased Risk of Infections After Immunosuppression in Patients with Inflammatory Bowel Diseases
- (2020) Bharati Kochar et al. GASTROENTEROLOGY
- AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis
- (2020) Joseph D. Feuerstein et al. GASTROENTEROLOGY
- Epidemiology and Pathogenesis of Ulcerative Colitis
- (2020) Lillian Du et al. GASTROENTEROLOGY CLINICS OF NORTH AMERICA
- EXTRA-INTESTINAL MANIFESTATIONS OF INFLAMMATORY BOWEL DISEASES
- (2020) Daniela Marotto et al. PHARMACOLOGICAL RESEARCH
- Ulcerative colitis
- (2020) Taku Kobayashi et al. Nature Reviews Disease Primers
- Frailty and Risk of Serious Infections in Biologic-treated Patients With Inflammatory Bowel Diseases
- (2020) Siddharth Singh et al. INFLAMMATORY BOWEL DISEASES
- Real-World Experience with Tofacitinib in IBD at a Tertiary Center
- (2019) Roni Weisshof et al. DIGESTIVE DISEASES AND SCIENCES
- Use of biosimilars in inflammatory bowel disease: A position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)
- (2019) Gionata Fiorino et al. DIGESTIVE AND LIVER DISEASE
- Conserved transcriptomic profile between mouse and human colitis allows unsupervised patient stratification
- (2019) Paulo Czarnewski et al. Nature Communications
- Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis
- (2019) William J. Sandborn et al. GASTROENTEROLOGY
- Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
- (2019) Bruce E. Sands et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
- (2019) Bruce E. Sands et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients with Ulcerative Colitis
- (2019) William J. Sandborn et al. GASTROENTEROLOGY
- Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis
- (2018) Stephen Hanauer et al. Clinical Gastroenterology and Hepatology
- The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy
- (2018) Alessandro Armuzzi et al. INFLAMMATORY BOWEL DISEASES
- Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN
- (2017) Oren Ledder et al. Journal of Crohns & Colitis
- Vedolizumab in IBD–Lessons From Real-world Experience; A Systematic Review and Pooled Analysis
- (2017) Tal Engel et al. Journal of Crohns & Colitis
- Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies
- (2017) Siew C Ng et al. LANCET
- Ulcerative colitis
- (2017) Ryan Ungaro et al. LANCET
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
- (2017) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease
- (2016) Lieven Pouillon et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future
- (2016) Daniela Pugliese et al. Expert Review of Clinical Immunology
- Next generation of small molecules in inflammatory bowel disease
- (2016) Pablo Olivera et al. GUT
- The safety of vedolizumab for ulcerative colitis and Crohn's disease
- (2016) Jean-Frédéric Colombel et al. GUT
- An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab
- (2016) Tim Wyant et al. Journal of Crohns & Colitis
- Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
- (2016) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Maintenance of Efficacy and Continuing Safety of Golimumab for Active Ulcerative Colitis: PURSUIT-SC Maintenance Study Extension Through 1 Year
- (2016) Peter R Gibson et al. Clinical and Translational Gastroenterology
- Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease
- (2015) T. Lobatón et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Familial Risk of Inflammatory Bowel Disease: A Population-Based Cohort Study 1977–2011
- (2015) Frederik Trier Moller et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Factors Associated With Poor Outcomes in Adults With Newly Diagnosed Ulcerative Colitis
- (2015) Walter Reinisch et al. Clinical Gastroenterology and Hepatology
- Safety and Efficacy of AJM300, an Oral Antagonist of α4 Integrin, in Induction Therapy for Patients With Active Ulcerative Colitis
- (2015) Naoki Yoshimura et al. GASTROENTEROLOGY
- Epidemiology and risk factors for IBD
- (2015) Ashwin N. Ananthakrishnan Nature Reviews Gastroenterology & Hepatology
- Cancers Complicating Inflammatory Bowel Disease
- (2015) Laurent Beaugerie et al. NEW ENGLAND JOURNAL OF MEDICINE
- Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis
- (2013) William J. Sandborn et al. GASTROENTEROLOGY
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
- (2013) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
- (2012) Luke Jostins et al. NATURE
- Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
- (2012) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Review article: defining remission in ulcerative colitis
- (2011) S. P. L. Travis et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis
- (2011) Jean Frédéric Colombel et al. GASTROENTEROLOGY
- Epidemiology and Natural History of Inflammatory Bowel Diseases
- (2011) Jacques Cosnes et al. GASTROENTEROLOGY
- Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
- (2011) William J. Sandborn et al. GASTROENTEROLOGY
- Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial
- (2011) W. Reinisch et al. GUT
- Ulcerative Colitis as A Progressive Disease: The Forgotten Evidence
- (2011) Joana Torres et al. INFLAMMATORY BOWEL DISEASES
- Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: A report of 21 cases
- (2011) Iván Guerra et al. Journal of Crohns & Colitis
- Risk factors and characteristics of extent progression in ulcerative colitis
- (2009) María Josefina Etchevers et al. INFLAMMATORY BOWEL DISEASES
- Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region
- (2009) Jeffrey C Barrett et al. NATURE GENETICS
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started